In this interview, Arwen Podesta, MD, DFAPA, DFASAM, describes how alcohol use disorder remains a significant burden for patients and the health care system, and that clinicians across specialties should...
Using real-world patient scenarios and current guideline recommendations, this session from Practical Updates in Primary Care outlines a structured primary care approach to diagnosing low back pain,...
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
A systematic review and meta-analysis evaluated whether pharmacist-led deprescribing interventions reduce polypharmacy and potentially inappropriate medications among older adults across care settings.
...
On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...
